MLTX
MoonLake Immunotherapeutics
Next earnings Aug 3, 2026 (before open) · consensus $-0.96 EPS
Last earnings +10.4% on 2026-05-11
$20.11
▼ -5.23%$21.22▼ -50.65%
over 1Y
L $6.25EODHDH $61.99
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-5.2%
1W+11.8%
1M+16.4%
3M+27.0%
YTD+77.6%
1Y-50.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 22 analysts
Buy
Conservative balance sheet (liabilities/equity 0.39x).
MoonLake Immunotherapeutics shows limited reported revenue, and -74.7% ROE.
Sources: SEC EDGAR (CIK 0001821586, latest 10-Q filed 2026-05-11) · EODHD · as of 6/24/2026, 5:24:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.